New 52 Week High Today

BetterLife Pharma Inc BETRF:OTCQB

*Data is delayed | Exchange | USD
Last | 05/06/24 EDT
0.093quote price arrow down-0.0022 (-2.352%)
Volume
59,400
52 week range
0.03 - 0.10
Loading...
  • Open0.10
  • Day High0.10
  • Day Low0.093
  • Prev Close0.0952
  • 52 Week High0.10
  • 52 Week High Date05/06/24
  • 52 Week Low0.03
  • 52 Week Low Date12/14/23

Key Stats

  • Market Cap8.247M
  • Shares Out88.68M
  • 10 Day Average Volume23,851.88
  • Dividend-
  • Dividend Yield-
  • Beta-1.21
  • YTD % Change93.91

KEY STATS

  • Open0.10
  • Day High0.10
  • Day Low0.093
  • Prev Close0.0952
  • 52 Week High0.10
  • 52 Week High Date05/06/24
  • 52 Week Low0.03
  • 52 Week Low Date12/14/23
  • Market Cap8.247M
  • Shares Out88.68M
  • 10 Day Average Volume23,851.88
  • Dividend-
  • Dividend Yield-
  • Beta-1.21
  • YTD % Change93.91

RATIOS/PROFITABILITY

  • EPS (TTM)-0.02
  • P/E (TTM)-5.92
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-3.043M
  • ROE (TTM)-312.53%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)106.81%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On BetterLife Pharma Inc

 

Profile

MORE
BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating...
Ahmad Doroudian Ph.D.
Chief Executive Officer, Director
Moira Ong
Chief Financial Officer
Address
1275 WEST 6TH AVENUE
Vancouver, BC
V6H 1A6
Canada